e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Improving asthma therapy - new findings in established and experimental treatment modalities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical outcome in patients treated with omalizumab during pre-approval period in France
M. Molimard, V. Le Gros (Bordeaux, Rueil-Malmaison, France)
Source:
Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Session:
Improving asthma therapy - new findings in established and experimental treatment modalities
Session type:
Thematic Poster Session
Number:
3642
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Molimard, V. Le Gros (Bordeaux, Rueil-Malmaison, France). Clinical outcome in patients treated with omalizumab during pre-approval period in France. Eur Respir J 2007; 30: Suppl. 51, 3642
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Long-term follow-up of patients under omalizumab initiated during the pre-approval period in France
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Clinical and economic outcomes following 52-week add-on omalizumab
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
The APEX study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Effect of excluding ICU-admission on clinical outcomes in a randomized control trial studying the effect of corticosteroids in patients hospitalized with CAP
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study
Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020
Year: 2021
MARTE: an observational study on clinical and sociodemographic characteristics of asthmatic patients receiving maintenance and rescue treatment in Spain
Source: International Congress 2018 – Asthma: clinical screening tools
Year: 2018
Clinical management improves the treatment outcome of MDR-TB patients
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
One year of mepolizumab in severe asthma in Italy: efficacy and safety
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Changes in prescriped inhaled COPD medication during a 3 year period in Denmark. A registry study
Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept